Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 27 August 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1669840

Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

This article is a correction to:

  1. The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

    1. Read original article
Ning Peng&#x;Ning Peng1†Lin-Feng Mao&#x;Lin-Feng Mao1†Jia-Yong Su&#x;Jia-Yong Su2†Shao-Ping Liu&#x;Shao-Ping Liu3†Jun-Jie OuJun-Jie Ou4Shu-Chang ChenShu-Chang Chen4Ze SuZe Su5Wen-Feng LiWen-Feng Li6Fu-Quan YangFu-Quan Yang6Yong-Heng ZhouYong-Heng Zhou1Le LiLe Li2Jian-Hong Zhong*&#x;Jian-Hong Zhong2*‡ on behalf of the GUIDANCE investigators
  • 1Hepatobiliary Surgery Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
  • 2Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China
  • 3Hepatobiliary Surgery Department, Guigang City People’s Hospital, Guigang, China
  • 4General Surgery Department, The People’s Hospital of Wuzhou, Wuzhou, China
  • 5Hepatobiliary Pancreatic Surgery Department, The First People’s Hospital of Nanning, Nanning, China
  • 6Hepatobiliary and Pancreatic Surgery Department, The First People’s Hospital of Yulin, Yulin, China

A Correction on
The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection

By Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J, Chen S-C, Su Z, Li W-F, Yang F-Q, Zhou Y-H, Li L and Zhong J-H (2025) Front. Immunol. 16:1593153. doi: 10.3389/fimmu.2025.1593153

In the published article, there was an error in Supplementary Tables 1 and 2. Several units and the order in which the baseline variables appear are written incorrectly. The supplementary material has been updated in the original article.

In the published article, there was also several errors in the text. In the Abstract, the hazard ratio of “1.46” was erroneous due to a typographical mistake. The accurate hazard ratio value is “1.046”.

A correction has been made to Abstract, Results, paragraph 1.This sentence previously stated:

“For both groups, the median recurrence-free survival (hazard ratio 1.46, 95%CI 0.58-1.90) and median overall survival (hazard ratio 1.06, 95%CI 0.42-2.67) were not reached, with no significant difference between the two groups.”

The corrected sentence appears below:

“For both groups, the median recurrence-free survival (hazard ratio 1.046, 95%CI 0.58-1.90) and median overall survival (hazard ratio 1.06, 95%CI 0.42-2.67) were not reached, with no significant difference between the two groups.”

In the Results, the hazard ratio of “1.46” was erroneous due to a typographical mistake. The accurate hazard ratio value is “1.046”.

A correction has been made to Results, Comparison of RFS and OS between tislelizumab with and without TKIs group, paragraph 6. This sentence previously stated:

“The median RFS between the tislelizumab group and the tislelizumab plus TKIs group was not reached, with no significant difference (HR 1.46, 95%CI 0.58–1.90, Figure 3A).”

The corrected sentence appears below:

“The median RFS between the tislelizumab group and the tislelizumab plus TKIs group was not reached, with no significant difference (HR 1.046, 95%CI 0.58–1.90, Figure 3A).”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, high-risk of recurrence, tislelizumab, recurrence-free survival, adjuvant therapy

Citation: Peng N, Mao L-F, Su J-Y, Liu S-P, Ou J-J, Chen S-C, Su Z, Li W-F, Yang F-Q, Zhou Y-H, Li L and Zhong J-H (2025) Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection. Front. Immunol. 16:1669840. doi: 10.3389/fimmu.2025.1669840

Received: 20 July 2025; Accepted: 08 August 2025;
Published: 27 August 2025.

Edited and reviewed by:

Takahiro Kodama, Osaka University, Japan

Copyright © 2025 Peng, Mao, Su, Liu, Ou, Chen, Su, Li, Yang, Zhou, Li and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jian-Hong Zhong, emhvbmdqaWFuaG9uZ0BneG11LmVkdS5jbg==

†These authors have contributed equally to this work

‡ORCID: Jian-Hong Zhong, orcid.org/0000-0002-1494-6396

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.